Biocon Chief: Roche Should Wake Up And Smell The Coffee
This article was originally published in Scrip
Executive Summary
Partners Biocon and Mylan have garnered about 26% market share between them for their biosimilar versions of trastuzumab in India, despite innovator Roche's alleged efforts to "fob off" competition.